Cite
Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial.
MLA
Uemura, Hiroji, et al. “Efficacy and Safety of Darolutamide in Japanese Patients with Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Group Analysis of the Phase III ARAMIS Trial.” International Journal of Clinical Oncology, vol. 26, no. 3, Mar. 2021, pp. 578–90. EBSCOhost, https://doi.org/10.1007/s10147-020-01824-5.
APA
Uemura, H., Matsushima, H., Kobayashi, K., Mizusawa, H., Nishimatsu, H., Fizazi, K., Smith, M., Shore, N., Tammela, T., Tabata, K., Matsubara, N., Iinuma, M., Uemura, H., Oya, M., Momma, T., Kawakita, M., Fukasawa, S., Kobayashi, T., Kuss, I., & Le Berre, M.-A. (2021). Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial. International Journal of Clinical Oncology, 26(3), 578–590. https://doi.org/10.1007/s10147-020-01824-5
Chicago
Uemura, Hiroji, Hisashi Matsushima, Kazuki Kobayashi, Hiroya Mizusawa, Hiroaki Nishimatsu, Karim Fizazi, Matthew Smith, et al. 2021. “Efficacy and Safety of Darolutamide in Japanese Patients with Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Group Analysis of the Phase III ARAMIS Trial.” International Journal of Clinical Oncology 26 (3): 578–90. doi:10.1007/s10147-020-01824-5.